MediWound (MDWD) COO Shmuel details option and RSU holdings in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd. executive Hess Shmuel, the company’s COO and Chief Commercial Officer, reported his existing equity stake in a Form 3 insider filing. The filing lists stock options to acquire 32,000, 32,681, 24,000 and 31,000 ordinary shares at exercise prices of $8.1292, $12.7290, $18.5400 and $17.6000, expiring between December 1, 2033 and March 4, 2036.
He also reports direct holdings of 4,085, 3,000 and 3,800 ordinary shares, which footnotes explain are tied to restricted share units granted in 2024, 2025 and 2026, each vesting over four years. The Form 3 establishes his current ownership position and does not show any recent share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Hess Shmuel
Role
COO & Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 32,000 shares (Direct);
Ordinary shares — 4,085 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
FAQ
What does MediWound (MDWD) COO Hess Shmuel report in this Form 3?
He reports his existing equity stake, including stock options and ordinary shares in MediWound. The filing lists several option grants and direct share holdings, outlining his current ownership position as an executive officer without showing new market transactions.
How many MediWound stock options does Hess Shmuel report holding?
He reports stock options linked to 32,000, 32,681, 24,000 and 31,000 underlying ordinary shares. These options have exercise prices between $8.1292 and $18.5400 and expire from December 2033 through March 2036, reflecting multiple long-term incentive grants.
How do the MediWound RSU grants to Hess Shmuel vest over time?
Each RSU grant vests 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting quarterly over the next three years. This four-year schedule applies to RSUs granted in 2024, 2025 and 2026.